New, super-sensitive blood tests can spot tiny amounts of PSA that older tests miss, letting doctors find cancer coming back much sooner—sometimes years before it would have been noticed before.

40

Pro

0

Against

Evidence from Studies

Supporting (1)

40

Community contributions welcome

40

Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review

Systematic Review

Human

2024 Apr 8

This study shows that using super-sensitive blood tests to spot tiny amounts of PSA after prostate surgery can warn doctors of cancer coming back much earlier than old tests could — and catching it early helps patients live longer.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review

Score: 40

DOI: 10.3390/biomedicines12040822

Similar Assertions

The PSA blood test isn't very good at telling the difference between harmless prostate changes and real cancer, so many men get scared and undergo painful tests they don't need.

1

0

79%

Prostate-specific antigen (PSA) levels in serum serve as a biomarker for prostate tissue abnormality, enabling detection of early-stage prostate cancer in asymptomatic individuals when anatomical obstruction has not yet occurred.

40

0

76%

Testing men for prostate cancer with PSA blood tests might save a few lives, but it often finds cancers that would never cause harm, leading to unnecessary treatments with side effects.

1

0

72%